出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年6月
動物用原薬市場 : API の種類 [抗菌薬 (フルオロキノロン、テトラサイクリン)、ワクチン、ホルモン、抗菌薬、抗炎症薬、ホルモン]、合成の種類、投与経路、動物の種類 – 2028年までの世界予測
Veterinary API Market by API Type (Antimicrobials (Fluoroquinolones, Tetracyclines), Vaccines, Hormones, Antimicrobials, Anti-inflammatory, Hormones), Synthesis Type, Route of Administration, and Animal Type – Global Forecast to 2028
| ページ数 | 272 |
| 図表数 | 315 |
| 種別 | 英文調査報告書 |
| 価格 |
The global Veterinary API Market is estimated to grow significantly. By 2028, it is projected to reach a value of USD 7.1 billion, showing a compound annual growth rate (CAGR) of 6.5% during the forecast period, starting from USD 5.2 billion in 2023. The expansion of the Veterinary API Market is driven by various factors, including rising incidence of transboundary & zoonotic diseases, increasing animal population and pet ownership, and increasing disease control & disease prevention measures.
“Chemical based API segment was dominated by the highest share in Veterinary API Market”
The Veterinary API Market is divided into three types based on synthesis types such as Chemical based API, Biological API, and Highly potent API. The Chemical based API segment accounted for the highest share of the global Veterinary API Market in 2022. Increasing Demand for Plasma-Derived Medicinal Products, Advancements in Plasma Fractionation Technologies, and Growing Need for Cold Chain Infrastructure all some of the factors that are anticipated to promote market expansion throughout the projected period. Growing demand for veterinary medicines, occurrence of new or emerging infectious diseases, and increasing research and development activities are some of the factors that are anticipated to promote market expansion throughout the projected period.
“Companion animal segment was dominated by the highest share in Veterinary API Market”
The Veterinary API Market, based on Animal Type is divided into two types such as companion animals and livestock animals. In 2022, companion animals held the highest market share for Veterinary API Market. Growing emphasis on preventive healthcare for companion animals and Increasing pet ownership are some of the factors that contribute to the big proportion of this market.
“Asia Pacific is expected to witness the fastest growth in the forecast period.”
In the forecast period, Asia Pacific in the Veterinary API Market will have the fastest rising regional growth. Large number of veterinary hospitals and healthcare facilities, increasing spread of diseases in animals, and rising manufacturing infrasturcture for veterinary API manufacturing are the main factors driving market growth. Asia Pacific region has experienced an increase in pet ownership, coupled with a rising awareness of animal health and welfare. This has led to a higher demand for veterinary medicines and APIs in the region. Many countries in the Asia Pacific region, such as China, India, and South Korea, have seen substantial economic growth and increased disposable income. This has resulted in a greater ability and willingness to invest in the healthcare of companion animals, driving the expansion of veterinary API manufacturing infrastructure.
Following is a list of the major players (supply-side) in the Veterinary API Marketthat this study refers to: By Company Type: Tier 1- 34%, Tier 2- 46%, and Tier 3- 20% By Designation: C-level- 35%, Director Level—25%, and Others- 40% By Region: North America-30%, Europe-45%, Asia Pacific-20%, Latin America- 3%, and Middle East and Africa-2% Several of the major companies in the market for Veterinary API Market includes Phibro Animal Health Corporation (US), Fabbrica Italiana Sintetici S.p.A. (Italy), Sequent Scientific Ltd. (India), Excel Industries Ltd. (India), NGL Fine-Chem Ltd. (India), Insulnsud Pharma (Spain), Menadiona Sl (Spain), Rochem International Inc. (US), and Shaanxi Hanjiang Pharmaceutical Group Co. Ltd. (China)
Research Coverage:
The market study analyzes the main market segments for Veterinary APIs. The objective of this study is to estimate the market’s size and growth potential across several categories according to API Type, Synthesis Type, Route of Administration, and Animal Type. The report also provides a thorough competition analysis of the major market participants, together with company profiles, major insights regarding their product and service offerings, recent advancements, and key market strategies.
Key Benefits of Buying the Report:
The study provides data regarding the Veterinary API Market’s closest approximations and its segments, which will benefit market leaders and new entrants. This study will assist stakeholders in comprehending the competitive environment, obtaining insights to better position of their businesses, and developing appropriate go-to-market strategies. The research will also assist stakeholders in obtaining insights into the market’s pulse and learning about its major drivers, inhibitors, opportunities, and problems.
The report provides insights on the following pointers:
Analysis of key drivers (Rising incidence of transboundary & zoonotic diseases, increasing animal population and pet ownership, and increasing disease control & disease prevention measures), restraints (High costs of veterinary diagnostic and treatment) opportunities (Rising awareness about animal health and welfare and Untapped emerging economies), and challenges (Challenges In Large Molecule APIs Synthesis) influencing the growth of the Veterinary API Market.
Product Development/innovation:
Comprehensive details on new technologies, R&D initiatives, and product and service launches for Veterinary API Market
Market Development:
Comprehensive data on attractive markets, and the research analyzes the global Veterinary API Market
Market Diversification:
Detailed information on emerging products and services, unexplored regions, current trends, and investments in the Veterinary API Market.
Competitive Assessment:
Comprehensive analysis of market shares, growth plans, and service offerings of major companies operating in the Veterinary API Market like Phibro Animal Health Corporation (US), Fabbrica Italiana Sintetici S.p.A. (Italy), Sequent Scientific Ltd. (India), Excel Industries Ltd. (India), NGL Fine-Chem Ltd. (India)
目次
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
FIGURE 1 VETERINARY API MARKET SEGMENTATION 33
FIGURE 2 VETERINARY API MARKET, BY REGION 33
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 35
1.4.1 RECESSION IMPACT 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 3 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 38
FIGURE 4 PRIMARY SOURCES 39
2.1.2.1 Key data from primary sources 40
2.1.2.2 Key industry insights 40
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 41
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 42
FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 8 REVENUE SHARE ANALYSIS FOR PHIBRO ANIMAL HEALTH CORPORATION (2022) 43
FIGURE 9 VETERINARY API MARKET: SUPPLY-SIDE ANALYSIS (2022) 43
FIGURE 10 VETERINARY API MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES AND THEIR IMPACT ON MARKET GROWTH AND CAGR (2023–2028) 45
FIGURE 11 VETERINARY API MARKET: CAGR PROJECTIONS (2023–2028) 46
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 47
FIGURE 12 DATA TRIANGULATION METHODOLOGY 47
2.4 MARKET SHARE ANALYSIS 47
2.5 RESEARCH ASSUMPTIONS 48
TABLE 1 RESEARCH ASSUMPTIONS 48
2.6 RISK ASSESSMENT 48
2.7 LIMITATIONS 49
2.8 RECESSION IMPACT ANALYSIS 49
3 EXECUTIVE SUMMARY 50
FIGURE 13 VETERINARY API MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 14 VETERINARY API MARKET, BY SYNTHESIS TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 15 VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 16 VETERINARY API MARKET, BY ANIMAL TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 17 VETERINARY API MARKET: GEOGRAPHIC SNAPSHOT, 2022 53
4 PREMIUM INSIGHTS 54
4.1 VETERINARY API MARKET OVERVIEW 54
FIGURE 18 GROWING PREVALENCE OF ANIMAL DISEASES AND RISING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS TO DRIVE MARKET 54
4.2 ASIA PACIFIC: VETERINARY API MARKET, BY TYPE AND COUNTRY (2022) 55
FIGURE 19 PARASITICIDES ACCOUNTED FOR LARGEST SHARE OF APAC VETERINARY API MARKET IN 2022 55
4.3 VETERINARY API MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 56
4.4 VETERINARY API MARKET: REGIONAL MIX 57
FIGURE 21 NORTH AMERICA TO CONTINUE TO DOMINATE VETERINARY API MARKET IN 2022 57
4.5 VETERINARY API MARKET: EMERGING ECONOMIES VS. DEVELOPED COUNTRIES 57
FIGURE 22 EMERGING ECONOMIES TO OFFER GROWTH OPPORTUNITIES TO MARKET PLAYERS DURING FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
FIGURE 23 VETERINARY API MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.2.1 DRIVERS 59
5.2.1.1 Rising incidence of transboundary and zoonotic diseases 59
5.2.1.2 Increasing animal population and pet ownership 59
FIGURE 24 US: INCREASING PET EXPENDITURE, 2010–2021 (USD BILLION) 60
5.2.1.3 Increasing disease control and prevention measures 60
5.2.1.4 Growing demand for animal protein 60
5.2.2 RESTRAINTS 61
5.2.2.1 Regulations restricting use of parasiticides on food-producing animals 61
5.2.2.2 Growing concerns about antibiotic resistance 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Untapped emerging economies 62
5.2.4 CHALLENGES 62
5.2.4.1 Challenges in large-molecule API synthesis 62
5.2.4.2 High costs of veterinary diagnostics and treatment 62
5.3 INDUSTRY TRENDS 63
5.3.1 GROWING FRAGMENTATION IN VETERINARY API INDUSTRY 63
5.4 PRICING ANALYSIS 63
5.4.1 AVERAGE SELLING PRICE, BY TYPE 63
TABLE 2 AVERAGE SELLING PRICE, BY TYPE (USD) 63
5.4.2 AVERAGE SELLING PRICE TRENDS 63
5.5 SUPPLY CHAIN ANALYSIS 64
FIGURE 25 SUPPLY CHAIN ANALYSIS: VETERINARY API MARKET 65
5.6 ECOSYSTEM ANALYSIS 65
FIGURE 26 ECOSYSTEM ANALYSIS: VETERINARY API MARKET 65
5.7 PATENT ANALYSIS 66
FIGURE 27 PATENT PUBLICATION TRENDS (JANUARY 2013–MAY 2023) 66
5.7.1 TOP APPLICANTS (COMPANIES/INSTITUTES) 66
FIGURE 28 VETERINARY API MARKET: TOP APPLICANTS (COMPANIES/INSTITUTES) FOR PATENTS (2013–2023) 66
5.8 VALUE CHAIN ANALYSIS 67
FIGURE 29 VALUE CHAIN ANALYSIS: VETERINARY API MARKET 67
5.9 CASE STUDIES 68
5.9.1 IDENTIFYING BUSINESS OPPORTUNITIES IN BROAD-SPECTRUM PARASITICIDES, US 68
5.10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 5 ASIA PACIFIC AND ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
5.11 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 6 PORTER’S FIVE FORCES ANALYSIS: VETERINARY API MARKET 72
5.11.1 INTENSITY OF COMPETITIVE RIVALRY 72
5.11.2 BARGAINING POWER OF SUPPLIERS 72
5.11.3 BARGAINING POWER OF BUYERS 72
5.11.4 THREAT OF NEW ENTRANTS 73
5.11.5 THREAT OF SUBSTITUTES 73
5.12 ADJACENT MARKET ANALYSIS 74
FIGURE 30 ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET: MARKET OVERVIEW 74
5.13 KEY CONFERENCES & EVENTS IN 2023–2024 75
TABLE 7 VETERINARY API MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 75
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 76
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE API TYPES 76
TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE API TYPES 76
5.14.2 BUYING CRITERIA 77
TABLE 9 KEY BUYING CRITERIA FOR TOP THREE API TYPES 77
5.15 TRADE ANALYSIS 78
TABLE 10 TOP 10 IMPORTERS OF ANTIBIOTICS (HS CODE–2941) 78
TABLE 11 TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE–2941) 78
TABLE 12 TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE–2937) 79
TABLE 13 TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE–2937) 79
5.16 IMPACT OF RECESSION ON VETERINARY API MARKET 80
6 VETERINARY API MARKET, BY TYPE 81
6.1 INTRODUCTION 82
TABLE 14 VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 82
6.2 PARASITICIDES 82
TABLE 15 PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 16 PARASITICIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
6.2.1 ALBENDAZOLE & FENBENDAZOLE 84
6.2.1.1 Growing prevalence of infections in animals to boost adoption 84
TABLE 17 ALBENDAZOLE & FENBENDAZOLE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.2.2 IVERMECTIN 85
6.2.2.1 Effectiveness in treating parasitic infections to drive market 85
TABLE 18 IVERMECTIN MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.2.3 PRAZIQUANTEL 86
6.2.3.1 Growing resistance to other treatment options to drive demand 86
TABLE 19 PRAZIQUANTEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
6.2.4 LEVAMISOLE 87
6.2.4.1 Cost-effectiveness to drive usage in parasitic infection treatment 87
TABLE 20 LEVAMISOLE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.2.5 OTHER PARASITICIDES 88
TABLE 21 OTHER PARASITICIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.3 VACCINES 89
TABLE 22 VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 89
TABLE 23 VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.3.1 CANINE PARVOVIRUS & CANINE DISTEMPER VIRUS VACCINES 91
6.3.1.1 Availability of effective vaccines against highly contagious diseases to drive market 91
TABLE 24 CPV & CDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
6.3.2 NEWCASTLE DISEASE VIRUS VACCINES 92
6.3.2.1 Need to ensure poultry health to boost vaccine usage 92
TABLE 25 NDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.3.3 INFECTIOUS BURSAL DISEASE VIRUS VACCINES 93
6.3.3.1 Veterinarian recommendations to drive vaccine demand 93
TABLE 26 IBDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
6.3.4 FELINE LEUKEMIA VIRUS VACCINES 94
6.3.4.1 Rising feline population to drive market 94
TABLE 27 FELV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
6.3.5 OTHER VACCINES 95
TABLE 28 OTHER VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.4 ANTIMICROBIALS 96
TABLE 29 ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 30 ANTIMICROBIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
6.4.1 BETA-LACTAMS 97
6.4.1.1 Rising incidence of zoonotic diseases in livestock to drive demand for beta-lactams 97
TABLE 31 BETA-LACTAMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
6.4.2 TETRACYCLINES 98
6.4.2.1 Decreasing prices to support demand growth 98
TABLE 32 TETRACYCLINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.4.3 AMINOGLYCOSIDES 99
6.4.3.1 Growing food-producing animal population to boost demand 99
TABLE 33 AMINOGLYCOSIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
6.4.4 FLUOROQUINOLONES 100
6.4.4.1 Compatibility with different routes of administration to ensure sustained market growth 100
TABLE 34 FLUOROQUINOLONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
6.4.5 OTHER ANTIMICROBIALS 101
TABLE 35 OTHER ANTIMICROBIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.5 ANTI-INFLAMMATORIES 102
TABLE 36 ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 37 ANTI-INFLAMMATORIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.5.1 MELOXICAM & PIROXICAM 104
6.5.1.1 Relatively low side-effect profiles to drive market growth 104
TABLE 38 MELOXICAM & PIROXICAM MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.5.2 CARPROFEN 105
6.5.2.1 Wide treatment applications to drive market 105
TABLE 39 CARPROFEN MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.5.3 DERACOXIB & FIROCOXIB 106
6.5.3.1 Effectiveness in pain relief and inflammation to boost demand 106
TABLE 40 DERACOXIB & FIROCOXIB MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.5.4 OTHER ANTI-INFLAMMATORIES 107
TABLE 41 OTHER ANTI-INFLAMMATORIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
6.6 HORMONES 108
TABLE 42 HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 43 HORMONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.6.1 PROGESTERONE & TESTOSTERONE 109
6.6.1.1 Progesterone & testosterone to hold largest share of hormones market over forecast period 109
TABLE 44 PROGESTERONE & TESTOSTERONE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
6.6.2 ESTRADIOL 110
6.6.2.1 Wide applications in regulating animal reproductive functions to drive market 110
TABLE 45 ESTRADIOL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.6.3 LUTEINIZING HORMONE 111
6.6.3.1 Wide usage in assisted reproduction to ensure continued demand 111
TABLE 46 LUTEINIZING HORMONE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
6.6.4 OTHER HORMONES 112
TABLE 47 OTHER HORMONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.7 OTHER VETERINARY APIS 113
TABLE 48 OTHER VETERINARY APIS, BY COUNTRY, 2021–2028 (USD MILLION) 113
7 VETERINARY API MARKET, BY SYNTHESIS TYPE 114
7.1 INTRODUCTION 115
TABLE 49 VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 115
7.2 CHEMICAL-BASED API 116
7.2.1 CHEMICAL-BASED API TO HOLD LARGEST SHARE OVER FORECAST PERIOD 116
TABLE 50 CHEMICAL-BASED VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
7.3 BIOLOGICAL API 117
7.3.1 GROWING INDUSTRY RECOGNITION TO DRIVE FOCUS ON BIOLOGICAL API PRODUCTION 117
TABLE 51 BIOLOGICAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
7.4 HIGHLY POTENT API 118
7.4.1 RISING NEED FOR ADVANCED TREATMENT AND IMPROVED OUTCOMES TO DRIVE MARKET 118
TABLE 52 HIGHLY POTENT VETERINARY API MARKET, BY COUNTRY 2021–2028 (USD MILLION) 118
8 VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION 119
8.1 INTRODUCTION 120
TABLE 53 VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 120
8.2 ORAL 120
8.2.1 CONVENIENCE AND EASE OF ADMINISTRATION TO SUSTAIN DEMAND 120
TABLE 54 ORAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
8.3 INJECTABLE 121
8.3.1 RAPID ONSET OF ACTION AND PRECISE DOSAGE AND DELIVERY TO BOOST DEMAND FOR INJECTABLES 121
TABLE 55 INJECTABLE VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8.4 TOPICAL 122
8.4.1 OPTIMIZED, TARGETED DELIVERY CAPABILITIES TO DRIVE GROWTH 122
TABLE 56 TOPICAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
8.5 OTHER ROUTES 123
TABLE 57 VETERINARY API MARKET FOR OTHER ROUTES, BY COUNTRY, 2021–2028 (USD MILLION) 124
9 VETERINARY API MARKET, BY ANIMAL TYPE 125
9.1 INTRODUCTION 126
TABLE 58 VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 126
9.2 COMPANION ANIMALS 126
9.2.1 COMPANION ANIMALS SEGMENT TO DOMINATE MARKET, BY ANIMAL TYPE 126
TABLE 59 VETERINARY API MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2021–2028 (USD MILLION) 127
9.3 LIVESTOCK ANIMALS 127
9.3.1 FOCUS ON OPTIMIZING PRODUCTION AND PREVENTING OUTBREAKS TO DRIVE MARKET 127
TABLE 60 VETERINARY API MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2021–2028 (USD MILLION) 128
10 VETERINARY API MARKET, BY REGION 129
10.1 INTRODUCTION 130
FIGURE 32 VETERINARY API MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 130
TABLE 61 VETERINARY API MARKET, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 62 VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
10.2 NORTH AMERICA 132
FIGURE 33 NORTH AMERICA: VETERINARY API MARKET SNAPSHOT 133
10.2.1 NORTH AMERICA: RECESSION IMPACT 134
TABLE 63 NORTH AMERICA: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 64 NORTH AMERICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 65 NORTH AMERICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 66 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 67 NORTH AMERICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 68 NORTH AMERICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 69 NORTH AMERICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 70 NORTH AMERICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 136
TABLE 71 NORTH AMERICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 137
TABLE 72 NORTH AMERICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 137
10.2.2 US 137
10.2.2.1 Growing demand for veterinary APIs to drive market 137
TABLE 73 US: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 74 US: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 75 US: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 76 US: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 77 US: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 78 US: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 79 US: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 140
TABLE 80 US: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 140
TABLE 81 US: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 141
10.2.3 CANADA 141
10.2.3.1 Increasing number of pets in Canada to boost the market 141
TABLE 82 CANADA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 83 CANADA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 84 CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 85 CANADA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 86 CANADA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 87 CANADA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 88 CANADA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 143
TABLE 89 CANADA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 144
TABLE 90 CANADA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 144
10.3 EUROPE 145
10.3.1 EUROPE: RECESSION IMPACT 145
TABLE 91 EUROPE: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 92 EUROPE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 93 EUROPE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 94 EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 95 EUROPE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 96 EUROPE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 97 EUROPE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 98 EUROPE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 148
TABLE 99 EUROPE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 148
TABLE 100 EUROPE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 149
10.3.2 GERMANY 149
10.3.2.1 Germany to hold largest market share in Europe 149
TABLE 101 GERMANY: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 102 GERMANY: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 103 GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 104 GERMANY: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 105 GERMANY: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 106 GERMANY: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 107 GERMANY: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 151
TABLE 108 GERMANY: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 152
TABLE 109 GERMANY: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 152
10.3.3 FRANCE 152
10.3.3.1 Strong animal welfare regulations to drive market 152
TABLE 110 FRANCE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 111 FRANCE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 112 FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 113 FRANCE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 114 FRANCE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 115 FRANCE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 116 FRANCE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 155
TABLE 117 FRANCE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 155
TABLE 118 FRANCE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 156
10.3.4 UK 156
10.3.4.1 Focus on preventive care to drive market 156
TABLE 119 UK: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 120 UK: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 121 UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 122 UK: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 123 UK: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 124 UK: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 125 UK: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 158
TABLE 126 UK: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 159
TABLE 127 UK: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 159
10.3.5 ITALY 159
10.3.5.1 Increasing prevalence of animal diseases to drive market 159
TABLE 128 ITALY: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 129 ITALY: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 130 ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 131 ITALY: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 132 ITALY: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 133 ITALY: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 134 ITALY: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 162
TABLE 135 ITALY: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 162
TABLE 136 ITALY: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 163
10.3.6 SPAIN 163
10.3.6.1 Growing focus on animal health in Spain to support growth 163
TABLE 137 SPAIN: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 138 SPAIN: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 139 SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 140 SPAIN: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 141 SPAIN: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 142 SPAIN: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 143 SPAIN: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 165
TABLE 144 SPAIN: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 166
TABLE 145 SPAIN: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 166
10.3.7 REST OF EUROPE 166
TABLE 146 REST OF EUROPE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 147 REST OF EUROPE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 148 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 149 REST OF EUROPE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 150 REST OF EUROPE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 151 REST OF EUROPE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 152 REST OF EUROPE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 169
TABLE 153 REST OF EUROPE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 169
TABLE 154 REST OF EUROPE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 170
10.4 ASIA PACIFIC 170
FIGURE 34 ASIA PACIFIC: VETERINARY API MARKET SNAPSHOT 171
10.4.1 ASIA PACIFIC: RECESSION IMPACT 172
TABLE 155 ASIA PACIFIC: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 156 ASIA PACIFIC: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 157 ASIA PACIFIC: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 158 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 159 ASIA PACIFIC: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 160 ASIA PACIFIC: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 161 ASIA PACIFIC: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 162 ASIA PACIFIC: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 174
TABLE 163 ASIA PACIFIC: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 175
TABLE 164 ASIA PACIFIC: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 175
10.4.2 CHINA 175
10.4.2.1 China to retain market leadership in APAC over forecast period 175
TABLE 165 CHINA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 166 CHINA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 167 CHINA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 168 CHINA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 169 CHINA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 170 CHINA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 171 CHINA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 178
TABLE 172 CHINA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 178
TABLE 173 CHINA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 179
10.4.3 JAPAN 179
10.4.3.1 Growing pet ownership and companion animal care to drive market 179
TABLE 174 JAPAN: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 175 JAPAN: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 176 JAPAN: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 177 JAPAN: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 178 JAPAN: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 179 JAPAN: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 180 JAPAN: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 181
TABLE 181 JAPAN: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 182
TABLE 182 JAPAN: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 182
10.4.4 INDIA 182
10.4.4.1 Expanding livestock industry and prevalence of veterinary diseases to support growth 182
TABLE 183 INDIA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 184 INDIA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 185 INDIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 186 INDIA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 187 INDIA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 188 INDIA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 189 INDIA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 185
TABLE 190 INDIA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 185
TABLE 191 INDIA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 186
10.4.5 SOUTH KOREA 186
10.4.5.1 Increasing awareness of animal health to drive market 186
TABLE 192 SOUTH KOREA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 193 SOUTH KOREA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 194 SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 195 SOUTH KOREA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 196 SOUTH KOREA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 197 SOUTH KOREA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 198 SOUTH KOREA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 188
TABLE 199 SOUTH KOREA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 189
TABLE 200 SOUTH KOREA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 189
10.4.6 AUSTRALIA 189
10.4.6.1 Well-developed veterinary services in Australia to drive market 189
TABLE 201 AUSTRALIA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 202 AUSTRALIA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 203 AUSTRALIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 204 AUSTRALIA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 205 AUSTRALIA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 206 AUSTRALIA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 207 AUSTRALIA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 192
TABLE 208 AUSTRALIA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 192
TABLE 209 AUSTRALIA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 193
10.4.7 REST OF ASIA PACIFIC 193
TABLE 210 REST OF ASIA PACIFIC: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 211 REST OF ASIA PACIFIC: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 212 REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 213 REST OF ASIA PACIFIC: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 214 REST OF ASIA PACIFIC: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 215 REST OF ASIA PACIFIC: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 216 REST OF ASIA PACIFIC: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 195
TABLE 217 REST OF ASIA PACIFIC: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 196
TABLE 218 REST OF ASIA PACIFIC: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 196
10.5 LATIN AMERICA 197
10.5.1 RISING LIVESTOCK AND COMPANION ANIMAL POPULATION TO BOOST DEMAND 197
10.5.2 LATIN AMERICA: RECESSION IMPACT 197
TABLE 219 LATIN AMERICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 220 LATIN AMERICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 221 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 222 LATIN AMERICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 223 LATIN AMERICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 224 LATIN AMERICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 225 LATIN AMERICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 199
TABLE 226 LATIN AMERICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 200
TABLE 227 LATIN AMERICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 200
10.6 MIDDLE EAST & AFRICA 200
10.6.1 RISING INCIDENCE OF PARASITIC INFECTIONS TO DRIVE DEMAND FOR TREATMENTS 200
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 201
TABLE 228 MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 229 MIDDLE EAST & AFRICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 230 MIDDLE EAST & AFRICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 231 MIDDLE EAST & AFRICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 232 MIDDLE EAST & AFRICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 233 MIDDLE EAST & AFRICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 234 MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION) 203
TABLE 235 MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 203
TABLE 236 MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION) 204
11 COMPETITIVE LANDSCAPE 205
11.1 OVERVIEW 205
11.2 KEY PLAYER STRATEGIES 205
FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY API MARKET 206
11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 206
FIGURE 36 REVENUE ANALYSIS FOR KEY PLAYERS IN VETERINARY API MARKET 207
11.4 MARKET SHARE ANALYSIS 207
FIGURE 37 VETERINARY API MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 208
TABLE 237 VETERINARY API MARKET: DEGREE OF COMPETITION 209
11.5 COMPANY EVALUATION MATRIX, 2022 210
11.5.1 STARS 210
11.5.2 PERVASIVE PLAYERS 210
11.5.3 EMERGING LEADERS 210
11.5.4 PARTICIPANTS 210
FIGURE 38 VETERINARY API MARKET: COMPANY EVALUATION MATRIX, 2022 211
11.6 COMPETITIVE BENCHMARKING 212
TABLE 238 OVERALL COMPANY FOOTPRINT 212
TABLE 239 COMPANY FOOTPRINT ANALYSIS, BY TYPE 213
TABLE 240 COMPANY FOOTPRINT ANALYSIS, BY SYNTHESIS TYPE 214
TABLE 241 COMPANY FOOTPRINT ANALYSIS, BY ROUTE OF ADMINISTRATION 215
TABLE 242 COMPANY FOOTPRINT ANALYSIS, BY ANIMAL TYPE 217
TABLE 243 COMPANY FOOTPRINT ANALYSIS, BY REGION 218
11.7 COMPETITIVE SCENARIO 219
11.7.1 PRODUCT LAUNCHES & APPROVALS 219
TABLE 244 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2023 219
11.7.2 DEALS 219
TABLE 245 DEALS, JANUARY 2021–MAY 2023 219
11.7.3 OTHER DEVELOPMENTS 220
TABLE 246 OTHER DEVELOPMENTS, JANUARY 2019- MAY 2023 220
12 COMPANY PROFILES 221
12.1 KEY PLAYERS 221
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 BOEHRINGER INGELHEIM GMBH 221
TABLE 247 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW 221
FIGURE 39 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2022) 222
12.1.2 ZOETIS, INC. 225
TABLE 248 ZOETIS, INC.: BUSINESS OVERVIEW 225
FIGURE 40 ZOETIS, INC.: COMPANY SNAPSHOT (2022) 226
12.1.3 ELANCO ANIMAL HEALTH INCORPORATED 228
TABLE 249 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW 228
FIGURE 41 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2022) 228
12.1.4 MERCK & CO., INC. 231
TABLE 250 MERCK & CO., INC.: BUSINESS OVERVIEW 231
FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT (2022) 232
12.1.5 VIRBAC 235
TABLE 251 VIRBAC: BUSINESS OVERVIEW 235
FIGURE 43 VIRBAC: COMPANY SNAPSHOT (2022) 236
12.1.6 VETOQUINOL S.A. 238
TABLE 252 VETOQUINOL S.A.: BUSINESS OVERVIEW 238
FIGURE 44 VETOQUINOL S.A.: COMPANY SNAPSHOT (2022) 238
12.1.7 SEQUENT SCIENTIFIC LIMITED 240
TABLE 253 SEQUENT SCIENTIFIC LIMITED: BUSINESS OVERVIEW 240
FIGURE 45 SEQUENT SCIENTIFIC LIMITED: COMPANY SNAPSHOT (2022) 241
12.1.8 PHIBRO ANIMAL HEALTH CORPORATION 243
TABLE 254 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW 243
FIGURE 46 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2022) 244
12.1.9 FABBRICA ITALIANA SINTETICI S.P.A. 246
TABLE 255 FABBRICA ITALIANA SINTETICI: BUSINESS OVERVIEW 246
FIGURE 47 FABBRICA ITALIANA SINTETICI: COMPANY SNAPSHOT (2022) 246
12.1.10 EXCEL INDUSTRIES LTD. 248
TABLE 256 EXCEL INDUSTRIES LTD.: BUSINESS OVERVIEW 248
FIGURE 48 EXCEL INDUSTRIES LTD.: COMPANY SNAPSHOT (2022) 249
12.1.11 NGL FINE-CHEM LTD. 251
TABLE 257 NGL FINE-CHEM: BUSINESS OVERVIEW 251
FIGURE 49 NGL FINE-CHEM: COMPANY SNAPSHOT (2022) 251
12.1.12 QILU PHARMACEUTICAL 254
TABLE 258 QILU PHARMACEUTICAL: BUSINESS OVERVIEW 254
12.1.13 OLON S.P.A. 256
TABLE 259 OLON S.P.A: BUSINESS OVERVIEW 256
12.1.14 SHANDONG LUKANG PHARMACEUTICAL CO., LTD. 258
TABLE 260 SHANDONG LUKANG PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW 258
12.1.15 ZHEJIANG HUADI PHARMACEUTICAL GROUP CO., LTD. 259
TABLE 261 ZHEJIANG HUADI PHARMACEUTICAL GROUP CO., LTD.: BUSINESS OVERVIEW 259
12.1.16 INSUD PHARMA 260
TABLE 262 INSUD PHARMA: BUSINESS OVERVIEW 260
12.1.17 MENADIONA SL 261
TABLE 263 MENADIONA SL: BUSINESS OVERVIEW 261
12.1.18 ROCHEM INTERNATIONAL, INC. 262
TABLE 264 ROCHEM INTERNATIONAL: BUSINESS OVERVIEW 262
12.1.19 AFTON PHARMA 264
TABLE 265 LIMITED AFTON PHARMA: BUSINESS OVERVIEW 264
12.1.20 SHAANXI HANJIANG PHARMACEUTICAL GROUP CO. LTD. 265
TABLE 266 SHAANXI HANJIANG PHARMACEUTICAL GROUP CO. LTD.: BUSINESS OVERVIEW 265
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 266
12.2.1 DALIAN LAUNCHER FINE CHEMICAL CO., LTD. 266
12.2.2 AMGIS LIFESCIENCE LTD. 267
12.2.3 D.H. ORGANICS 267
12.2.4 SIFLON DRUGS 268
12.2.5 SBD HEALTHCARE PVT. LTD. 268
12.2.6 CENTURY PHARMACEUTICALS LTD. 269
12.2.7 SIDHIV PHARMA 270
12.2.8 FERMION 271
12.2.9 CHEMINO PHARMA PRIVATE LIMITED 271
12.2.10 SUANFARMA 272
13 APPENDIX 273
13.1 DISCUSSION GUIDE 273
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
13.3 RELATED REPORTS 279
13.4 AUTHOR DETAILS 280